235 related articles for article (PubMed ID: 25986720)
21. Deriving health utility values from a randomized, double-blind, placebo-controlled trial of siltuximab in subjects with multicentric Castleman's disease.
Vernon M; Robinson D; Trundell D; Ishak J; Jen MH; Brazier J
Curr Med Res Opin; 2016 Jul; 32(7):1193-200. PubMed ID: 26972925
[TBL] [Abstract][Full Text] [Related]
22. The role of interleukin 6 in the pathogenesis and therapy of Castleman disease - an immunologist's perspective.
Milota T; Střížová Z; Sobotková M; Bartůňková J
Cas Lek Cesk; 2023; 162(2-3):106-111. PubMed ID: 37474295
[TBL] [Abstract][Full Text] [Related]
23. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.
van Rhee F; Fayad L; Voorhees P; Furman R; Lonial S; Borghaei H; Sokol L; Crawford J; Cornfeld M; Qi M; Qin X; Herring J; Casper C; Kurzrock R
J Clin Oncol; 2010 Aug; 28(23):3701-8. PubMed ID: 20625121
[TBL] [Abstract][Full Text] [Related]
24. The Role of Interleukin-6 in Castleman Disease.
Yoshizaki K; Murayama S; Ito H; Koga T
Hematol Oncol Clin North Am; 2018 Feb; 32(1):23-36. PubMed ID: 29157617
[TBL] [Abstract][Full Text] [Related]
25. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.
van Rhee F; Casper C; Voorhees PM; Fayad LE; Gibson D; Kanhai K; Kurzrock R
Lancet Haematol; 2020 Mar; 7(3):e209-e217. PubMed ID: 32027862
[TBL] [Abstract][Full Text] [Related]
26. JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease.
Patel M; Ikeda S; Pilat SR; Kurzrock R
JAMA Dermatol; 2017 May; 153(5):449-452. PubMed ID: 28241173
[TBL] [Abstract][Full Text] [Related]
27. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
Fajgenbaum DC
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):318-325. PubMed ID: 30504327
[TBL] [Abstract][Full Text] [Related]
28. Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease.
Casper C; Chaturvedi S; Munshi N; Wong R; Qi M; Schaffer M; Bandekar R; Hall B; van de Velde H; Vermeulen J; Reddy M; van Rhee F
Clin Cancer Res; 2015 Oct; 21(19):4294-304. PubMed ID: 26124203
[TBL] [Abstract][Full Text] [Related]
29. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease.
van Rhee F; Rosenthal A; Kanhai K; Martin R; Nishimura K; Hoering A; Fajgenbaum DC
Blood Adv; 2022 Aug; 6(16):4773-4781. PubMed ID: 35793409
[TBL] [Abstract][Full Text] [Related]
30. A Multicentric Castleman Disease Associated with Mixed Warm and Cold Antibody-Mediated AHA Responsive to Siltuximab.
Plano F; Mancuso S; Camarda GM; Butera MG; Sucato G; Alecci G; Florena AM; Perrone S; Siragusa SM
Chemotherapy; 2024; 69(1):35-39. PubMed ID: 37634492
[TBL] [Abstract][Full Text] [Related]
31. Siltuximab for Multicentric Castleman Disease-Letter.
Teipel R; Ordemann R; Proske U; Dietrich F; Mende M; Ehninger G; Kroschinsky F; Platzbecker U
Clin Cancer Res; 2015 Oct; 21(20):4740. PubMed ID: 26473194
[No Abstract] [Full Text] [Related]
32. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
Fajgenbaum DC
Blood; 2018 Nov; 132(22):2323-2330. PubMed ID: 30487129
[TBL] [Abstract][Full Text] [Related]
33. Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma.
Suzuki K; Ogura M; Abe Y; Suzuki T; Tobinai K; Ando K; Taniwaki M; Maruyama D; Kojima M; Kuroda J; Achira M; Iizuka K
Int J Hematol; 2015 Mar; 101(3):286-94. PubMed ID: 25655379
[TBL] [Abstract][Full Text] [Related]
34. First IL-6-blocking drug nears approval for rare blood disorder.
Williams SC
Nat Med; 2013 Oct; 19(10):1193. PubMed ID: 24100967
[No Abstract] [Full Text] [Related]
35. Siltuximab (CNTO 328): a promising option for human malignancies.
Chen R; Chen B
Drug Des Devel Ther; 2015; 9():3455-8. PubMed ID: 26170629
[TBL] [Abstract][Full Text] [Related]
36. Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy.
Cohen PR; Nikanjam M; Kato S; Goodman AM; Kurzrock R
Cureus; 2020 Jul; 12(7):e8967. PubMed ID: 32766009
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: A systematic review.
Rehman MEU; Chattaraj A; Neupane K; Rafae A; Saeed S; Basit J; Ibrahim A; Khouri J; Mukherjee S; Anwer F
Eur J Haematol; 2022 Oct; 109(4):309-320. PubMed ID: 35770616
[TBL] [Abstract][Full Text] [Related]
38. Treatment of Idiopathic Castleman Disease.
van Rhee F; Greenway A; Stone K
Hematol Oncol Clin North Am; 2018 Feb; 32(1):89-106. PubMed ID: 29157622
[TBL] [Abstract][Full Text] [Related]
39. Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report.
Yuan ZG; Dun XY; Li YH; Hou J
J Hematol Oncol; 2009 Apr; 2():19. PubMed ID: 19400935
[TBL] [Abstract][Full Text] [Related]
40. Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report.
Lang E; Sande B; Brodkin S; van Rhee F
Ther Adv Hematol; 2022; 13():20406207221082552. PubMed ID: 35251585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
